SEKISUI MEDICAL CO., LTD. Patent applications |
Patent application number | Title | Published |
20160138097 | METHOD FOR DETECTING METHYLATED DNA - Provided is a rapid and simple method of detecting methylated DNA. The method of detecting methylated DNA includes the following steps of: (1) treating sample DNA with a hydrogen sulfite; (2) amplifying the sample DNA treated with the hydrogen sulfite by PCR; and (3) subjecting the resultant PCR amplification product to ion-exchange chromatography. | 05-19-2016 |
20160061788 | SWITCHING VALVE FOR FLOW TYPE ANALYSIS APPARATUS - A switching valve includes: (A) a rotor including: (1) a center pipe connection port, (2) a first in-valve flow path in communication with the center pipe connection port, and (3) an arc-like second in-valve flow path; (B) a stator including: (4) a first pipe connection port group which is brought into communication independently with the center pipe connection port via the first in-valve flow path when the rotor is turned, and (5) a second pipe connection port group which is brought into mutual communication via the second in-valve flow path when the rotor is turned; and (C) an arrangement of the rotor and the stator satisfying the following relationship: the state of communication or non-communication among the second pipe connection port group via the second in-valve flow path is switched in accordance with the state of communication between the first pipe connection port group and the center pipe connection port. | 03-03-2016 |
20160041072 | SAMPLE INJECTION DEVICE FOR FLOW-TYPE ANALYSIS DEVICE, FLOW-TYPE ANALYSIS DEVICE, AND MEASUREMENT METHOD FOR HEMOGLOBIN COMPONENT - Provided is a sample injection device for flow-type analysis including a cylindrical needle ( | 02-11-2016 |
20160025706 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 01-28-2016 |
20160018419 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 01-21-2016 |
20150301038 | CONJUGATE FOR USE IN IMMUNOASSAY METHOD - To adjust detection sensitivity and expand a measurement range depending on objects to be detected by a simple procedure in an immunoassay method involving using a colloidal metal having immobilized thereon an antibody or an antigen. Blocking treatment for a surface of a colloidal metal particle having immobilized thereon an antibody or an antigen with both components, i.e., a component of biological origin and a component of non-biological origin enables adjustment of measurement sensitivity with, for example, kinds and concentrations of both the components, and enables use of the component of non-biological origin, which has not been usable alone because of aggregation of a colloidal metal. | 10-22-2015 |
20150293087 | ADDITIVE FOR MEASURING DILUTED SAMPLE IN NON-DILUTION-TYPE IMMUNOCHROMATOGRAPHIC METHOD REAGENT - Provided are: an immunoassay method in which the deviation from a theoretical value (hereinafter also referred to as “a reference value”), which may be caused when a diluted blood specimen is used as a sample, is reduced in an immunochromatographic method that is so designed that a blood specimen (whole blood, serum or plasma) is used directly as a sample without subjecting the blood specimen to any pretreatment such as a dilution treatment; and a reagent for use in the method. An immunochromatographic method performed on a blood specimen using an immunochromatographic device equipped with (1) a sample pad and (2) a membrane on which a component capable of specifically binding to an analyte is immobilized, arranged in the order of (1) and (2) from upstream, wherein hydroxyethyl starch is present in the measurement system. | 10-15-2015 |
20150253322 | IMMUNOLOGICAL DETECTION METHOD AND IMMUNOLOGICAL DETECTION REAGENT - An object of the present invention is to provide a method of detecting an analyte (antigen) in a sample by an antigen-antibody reaction with an antibody fragment including an antigen binding region for the analyte antigen (hereinafter “an antibody fragment comprising an antigen binding region for an analyte antigen” will simply be referred to as “an antibody fragment against antigen”), the method suppressing nonspecific reaction that is caused by antibody fragments. More specifically, provided is a method of detecting an analyte antigen in a sample by an antigen-antibody reaction with an antibody fragment against antigen, the method comprising the steps of: a) bringing a sample into contact with a denatured antibody fragment; and b) bringing the sample into contact with the antibody fragment immobilized on an insoluble carrier after the step of a), the method suppressing nonspecific reaction. | 09-10-2015 |
20150233906 | LATEX PARTICLES FOR PARTICLE AGGLUTINATION ASSAY - A particulate latex for high-sensitive agglutination assay that barely poses non-specific reactions and can readily prepare diagnostic reagents, and a reagent for agglutination assay including the particle are provided. A particulate latex for agglutination assay, including a first polymerizable monomer having a phenyl group, a second polymerizable monomer having a phenyl group and a salt of sulfonic acid, and a third polymerizable monomer represented by Formula (1): | 08-20-2015 |
20150212075 | LATEX AGGLUTINATION INHIBITION IMMUNOASSAY - A problem of the present invention is to provide a method capable of avoiding nonspecific reactions which result in the absence of agglutination that should occur in agglutination inhibition LTIA. The present invention provides a method of avoiding nonspecific reactions in a latex agglutination inhibition test by performing a latex agglutination inhibition assay in the presence of one or more compounds selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, and polyvalent quaternary amine polymer compounds. | 07-30-2015 |
20150185236 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 07-02-2015 |
20150185203 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 07-02-2015 |
20150111235 | METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME - Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. | 04-23-2015 |
20150086974 | IMMUNOCHROMATOGRAPHIC TEST STRIP AND DETECTION METHOD USING IMMUNOCHROMATOGRAPHY FOR DETECTING TARGET IN RED BLOOD CELL-CONTAINING SAMPLE - A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions. | 03-26-2015 |
20150080542 | LATEX PARTICLES FOR AGGLUTINATION ASSAY - A latex particle for high-sensitive agglutination assay and a reagent for agglutination assay including the particle are provided. The latex particle barely initiates non-specific reactions and can readily prepare diagnostic agents. A latex particle for agglutination assay including a polymerizable monomer having a phenyl group, a polymerizable monomer having a phenyl group and a salt of sulfonic acid, and a polymerizable monomer represented by Formula (1): | 03-19-2015 |
20150072367 | METHOD FOR MEASURING SUBSTANCE IN BLOOD SAMPLE - Provided is a method for measuring a substance in a blood sample, which allows avoidance of the influences of both of bilirubin and hemoglobin by simple operations. | 03-12-2015 |
20150064692 | IMMUNOCHROMATOGRAPHIC TEST STRIP AND DETECTION METHOD USING IMMUNOCHROMATOGRAPHY FOR DETECTING TARGET IN RED BLOOD CELL-CONTAINING SAMPLE - A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions. | 03-05-2015 |
20140363899 | METHOD FOR AVOIDING INFLUENCE OF ENDOGENOUS LIPOPROTEIN AND REAGENT - To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component. | 12-11-2014 |
20140363810 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 12-11-2014 |
20140287444 | METHOD OF LIPID ASSAY AND REAGENT FOR USE THEREIN - A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability. | 09-25-2014 |
20140162369 | METHOD FOR MEASURING HEMOGLOBINS - The present invention aims to provide a method of measuring hemoglobins which can measure hemoglobins in a short time at high accuracy. The present invention also aims to provide a method of measuring hemoglobin A1c, a method of simultaneously measuring hemoglobin A1c and hemoglobin F, a method of simultaneously measuring hemoglobin A1c and hemoglobin A2, and a method of simultaneously measuring hemoglobin A1c and abnormal hemoglobins, each utilizing the above-mentioned method of measuring hemoglobins by liquid chromatography. The present invention relates to a method of measuring hemoglobins by liquid chromatography. A column used in the method is filled with, as a column-packing material, cation-exchangeable particles including cross-linked polymer particles having a cation-exchange-group-containing polymer bonded to the surface of the cross-linked polymer particles, and the column shows a pressure value of 9.8×10 | 06-12-2014 |
20140147842 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS - An object of the present invention is to provide a method for rapidly and simply detecting single nucleotide polymorphisms. The present invention is a method for detecting single nucleotide polymorphisms, comprising analyzing wild-type and mutant-type products amplified by an AS-PCR method using ion-exchange chromatography. | 05-29-2014 |
20140141059 | PATCH - Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate | 05-22-2014 |
20140127727 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 05-08-2014 |
20140127726 | METHOD OF MEASURING BLOOD COAGULATION TIME TO DETECT LUPUS ANTICOAGULANTS - Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time. | 05-08-2014 |
20140127725 | METHOD FOR DETECTING LUPUS ANTICOAGULANTS - Provided is the development of a convenient LA detection method in which even a sample derived from a patient who receives anticoagulant therapy of warfarin, heparin or the like, is not affected by the anticoagulant therapy, discrimination from the deficiency of blood coagulation factors is enabled, and healthy person's plasma is not used. The method for detecting lupus anticoagulant includes the following steps (A), (B) and (C): (A) a step of adding a buffer solution composition containing blood coagulation factors to each of a blood sample and a diluted sample of the blood sample before measurement or at the time of measurement of the blood coagulation time; (B) a step of measuring the blood coagulation times for the various samples of step (A); and (C) a step of comparing the blood coagulation times for the various samples obtained in step (B). | 05-08-2014 |
20140127706 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene an;d at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 05-08-2014 |
20140113387 | METHOD OF INHIBITING NONSPECIFIC REACTION IN PIVKA-II ASSAY REAGENT - A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies. | 04-24-2014 |
20140088303 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL - Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below. | 03-27-2014 |
20140087365 | IMMUNOCHROMATOGRAPHIC DETECTION METHOD CAPABLE OF DETERMINING SAMPLE WITHOUT SPECIMEN AS IMPROPERLY OPERATED SAMPLE AND TEST STRIP USED THEREWITH - An object of the present invention is to provide an immunochromatographic detection method comprising a step of detecting the failure to add a specimen and an immunochromatographic test strip comprising a means for detecting the failure to add a specimen. The inventers provides an immunochromatographic detection method and an immunochromatographic test strip capable of detecting the failure to add a specimen through a step and a means using an antibody solid-phased on an insoluble membrane for capturing the complex of a component (control component) contained in the specimen other than the analyte and a label to which an antibody to the component is immobilized so as to detect the presence or absence of the control component, in an immunochromatographic detection method of detecting an analyte in a sample acquired by diluting the specimen. | 03-27-2014 |
20140080158 | METHOD FOR IMMUNOLOGICALLY MEASURING SOLUBLE LR11 - To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). | 03-20-2014 |
20140080143 | PSA ASSAY AND REAGENT THEREFOR - Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 μm but 0.40 μm or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and α1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter. | 03-20-2014 |
20140051102 | METHOD OF LIPID ASSAY AND REAGENT FOR USE THEREIN - A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability. | 02-20-2014 |
20140038213 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 02-06-2014 |
20130330735 | ELUENT FOR ION-EXCHANGE CHROMATOGRAPHY, AND METHOD OF ANALYZING NUCLEIC ACID CHAINS - The present invention provides eluent for ion-exchange chromatography, wherein the eluent allows separation and detection of a target nucleic acid such as a PCR-amplified product, a restriction enzyme fragment of the PCR-amplified product, or a restriction enzyme fragment of a nucleic acid in a short time with high separation performance. The present invention also provides a method of analyzing nucleic acid chains by ion-exchange chromatography using the eluent. The present invention provides an eluent for ion-exchange chromatography comprising a guanidine salt derived from guanidine represented by the following formula (1): | 12-12-2013 |
20130261572 | PATCH - Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0. | 10-03-2013 |
20130244314 | IMMUNOCHROMATOGRAPHIC TEST STRIP AND MANUFACTURING METHOD THEREOF - An immunochromatographic test strip that achieves a shorter reaction completion time and excellent sensitivity is provided. The immunochromatographic test strip comprises: (1) a conjugate pad comprising a sample-supplying section supplying a sample possibly containing an analyte and a line-shaped conjugate section containing a conjugate in which an antibody or antigen immunologically reactive with the analyte is immobilized to a label on the downstream side relative to the sample-supplying section; and (2) an insoluble membrane support having at least one detecting section to which an antibody or antigen immunologically reactive with the analyte is immobilized, the lower surface of the sample-supplying section of the conjugate pad being not in contact with the upper surface of the insoluble membrane support, the lower surface of the conjugate section of the conjugate pad being in contact with the upper surface of the insoluble membrane support. | 09-19-2013 |
20130210044 | METHOD OF LIPID ASSAY AND REAGENT FOR USE THEREIN - A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability. | 08-15-2013 |
20130202677 | PATCH - Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate | 08-08-2013 |
20130172200 | METHOD OF ASSESSING CANCEROUS CONDITIONS AND REAGENT FOR DETECTING GENE PRODUCT TO BE USED IN THE METHOD - A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample. | 07-04-2013 |
20130156793 | INSULIN-RESISTANCE-IMPROVING DRUG - Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3. | 06-20-2013 |
20130143812 | ANTI-INFLAMMATORY DRUG - Provided is a new anti-inflammatory drug that produces an anti-inflammatory effect by modulating macrophage function. Specifically, a new anti-inflammatory drug that produces an anti-inflammatory effect through induction of M2 macrophages using activin species is provided. | 06-06-2013 |
20130143748 | METHODS FOR DETECTION OF RISK OF OBESITY AND RISK OF ONSET OF DIABETES - Provided is a method of measuring the expression level of FSTL3 gene in a biological sample and correlating the measured expression level with the detection of a risk of developing diabetes. Also provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 not clinically determined as obesity and correlating the measured expression level with the detection of a risk of developing obesity. Further provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 and correlating the measured expression level with the detection of a risk of developing diabetes. Further provided is a method of measuring an inhibin βB gene expression level and correlating the ratio of expression level of FSTL3 gene to inhibin βB gene with the detection of a risk of developing obesity or diabetes. | 06-06-2013 |
20130143229 | REAGENT FOR ASSAYING ANTI-TREPONEMA PALLIDUM ANTIBODY - To provide a reagent for assaying anti- | 06-06-2013 |
20130115229 | METHOD FOR DETECTING MALIGNANT TUMOR CELLS - Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested. | 05-09-2013 |
20130052655 | ASSAY UTILIZING IMMUNOCHROMATOGRAPHY, IMMUNOCHROMATOGRAPHIC TEST STRIP, AND ASSAY REAGENT KIT FOR IMMUNOCHROMATOGRAPHY - The present invention provides a measurement method utilizing immunochromatography, an immunochromatographic test strip, and a reagent kit of immunochromatography capable of accurate short-time measurement of an analyte in blood with simple operations as compared to the conventional methods. The present invention provides a method of measurement by immunochromatography in which concentrations of an analyte and hemoglobin in the same sample are measured by immunochromatography to perform hematocrit correction of a measurement value of the analyte by using a measurement value of hemoglobin, as well as a test strip and a reagent kit for immunochromatography. | 02-28-2013 |
20130029429 | METHOD FOR AVOIDING INFLUENCE OF ENDOGENOUS LIPOPROTEIN AND REAGENT - To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component. | 01-31-2013 |
20130029363 | METHOD FOR DIAGNOSING MALIGNANT TUMOR - To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. | 01-31-2013 |
20130023061 | METHOD FOR STABILIZING GLYCEROPHOSPHOLIPIDS AND REAGENTS USING SAME - Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system. | 01-24-2013 |
20130004976 | HUMAN INSULIN ASSAY AND ASSAY REAGENT - A problem of the present invention is to provide an antibody specific to human insulin and an assay and an assay reagent using the antibody capable of accurately assaying human insulin without being affected by porcine insulin. The present invention provides an assay and an assay reagent capable of specifically assaying human insulin by combining a monoclonal antibody specifically reactive with human insulin and nonreactive with porcine insulin and a different anti-human insulin antibody. | 01-03-2013 |
20120322094 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 12-20-2012 |
20120258552 | HOMOGENEOUS MEASUREMENT METHOD AND MEASURING REAGENT - Provided is a homogenous measurement method using insoluble carrier particles that suppresses the matrix effect originating from the sample and also suppresses differences in measurement accuracy among different models of automated analyzers. Also provided is a measuring reagent for use in an automated analyzer. Inclusion of a silicone-based defoaming agent in the reagent reduces the matrix effect originating from the sample and reduces variability of measurement accuracy among different automated analyzers having differing specifications. | 10-11-2012 |
20120214988 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL - Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below. | 08-23-2012 |
20120149047 | METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS - A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers. | 06-14-2012 |
20120141672 | COATING APPARATUS AND LIQUID SUBSTANCE COATING METHOD - Provided is a coating apparatus in which a liquid substance is less likely to splash around and a chemical solution can be coated on a specific region of the inside surface of a tubular container. The coating apparatus | 06-07-2012 |
20120064553 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 03-15-2012 |
20120040476 | IMMUNOASSAY REAGENT FOR KL-6 ASSAY - The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized. | 02-16-2012 |
20120015388 | Diluent for Preparing Analytical Sample - The ionic strength of a diluent for preparing an analytical sample is set to be 0.06 to 0.16. The analytical sample prepared by using the diluent having the ionic strength within this range can be subjected to both for analyzing a first object in a test sample by electrode method and for analyzing a second object in the test sample by liquid chromatography method, and high-precision measurement can be attained. The analytical sample is especially useful for preparing a sample for measurement used both for measuring glucose concentration in a blood sample by enzyme electrode method and for measuring glycohemoglobin concentration in the blood sample by liquid chromatography method. | 01-19-2012 |
20110318765 | METHOD FOR PRE-TREATING SAMPLE CONTAINING GLYCATED HEMOGLOBIN - There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. | 12-29-2011 |
20110311989 | ANTIBODY TO N-TERMINAL REGION OF HEMOGLOBIN BETA-CHAIN - Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified. | 12-22-2011 |
20110250653 | L-SUCCINYLAMINOACYLASE AND PROCESS FOR PRODUCING L-AMINO ACID USING IT - The present invention provides a L-succinylacylase consisting of: (a) a protein coded by a gene consisting of a nucleic acid sequence shown in SEQ ID No: 1; (b) a protein consisting of an amino acid sequence shown in SEQ ID No: 2; (c) a protein coded by a polynucleotide which hybridizes under a stringent condition with a nucleic acid sequence which is complementary to the nucleic acid sequence shown in SEQ ID No: 1 and having an L-succinylaminoacylase activity; or (d) a protein which consists of an amino acid sequence where one or several amino acid(s) is/are substituted, deleted, inserted and/or added in the protein consisting of the amino acid sequence shown in SEQ ID No: 2 and has an L-succinylaminoacylase activity. This enzyme is able to produce a sterically bulky unnatural amino acid such as L-tert-leucine etc. which is useful as an intermediate for pharmaceuticals. | 10-13-2011 |
20110244530 | L-SUCCINYLAMINOACYLASE AND PROCESS FOR PRODUCING L-AMINO ACID USING IT - The present invention provides an L-aminoacylase which is able to produce L-tert-leucine being useful as an intermediate for pharmaceuticals. | 10-06-2011 |
20110236996 | METHOD FOR MEASURING CYSTATIN C IN HUMAN BODY FLUID - There is provided a particle-enhanced immunoassay method for cystatin C in a human body fluid, which has higher specificity and is easily automatable at low cost as compared with conventional assay methods that use large amounts of polyclonal antibodies having low specificity or monoclonal antibodies having high specificity but having poor agglutinability. | 09-29-2011 |
20110186511 | LIQUID CHROMATOGRAPHY APPARATUS AND LIQUID CHROMATOGRAPHY - A liquid chromatography apparatus is provided with a sample preparation unit, a column that separates components of a sample, an eluent supplier that includes a feeder for supplying eluents to the column, a flow path directional valve capable of introducing fixed amounts of the sample and the eluents to the column, an analyzer for analyzing a test solution composed of the sample components separated by the column and one of the eluents, and a controller, wherein the eluent supplier supplies the eluents to the flow path directional valve in an unmixed state. As a result of employing this configuration, analysis time is shortened and eluent consumption is reduced. | 08-04-2011 |
20110177610 | NOVEL MARKER FOR ARTERIOSCLEROTIC DISEASE - Disclosed is a novel marker for an arteriosclerotic disease. Also disclosed is a method for evaluating the presence or level of an arteriosclerotic disease in a mammal, or a method for evaluating the prophylactic or therapeutic effect on an arteriosclerotic disease in a mammal, which is characterized by detecting a soluble LR11 in a sample collected from the mammal. | 07-21-2011 |
20110152573 | PROCESS FOR PRODUCING N-PROTECTED AMINO ACID - The present invention relates to a method for producing N-protected amino acid. Specifically, the present invention provides a method in which a protecting group is introduced to the amino group of an amino acid in a reaction under alkaline condition, and the N-protected amino acid thus generated is then separated from the reaction solution as crystals, without undergoing an extraction step or a concentration step. The present inventors have completed the invention based on the finding that desirable crystals of N-protected amino acids may be obtained without extraction, concentration or recrystallization steps between the initial generation of the N-protected amino acid molecules and the subsequent separation of the crystals, by first adding an water-soluble organic solvent and optionally water to the reaction solution (alkaline) containing the N-protected amino acid, and then neutralizing the solution by an acid. | 06-23-2011 |
20110129862 | METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME - Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. | 06-02-2011 |
20110104825 | METHOD FOR ENHANCING SENSITIVITY OR METHOD FOR AVOIDING INFLUENCE OF HEMOGLOBIN IN IMMUNOLOGICAL MEASUREMENT - To provide a technique for enhancing measurement sensitivity or a technique for avoiding a hemoglobin influence in an immunoassay method. | 05-05-2011 |
20110104709 | POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME - A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant. | 05-05-2011 |
20110098475 | FLUORESCENT PROBES - A fluorescent probe which is represented by the following formula (wherein R | 04-28-2011 |
20110091993 | METHOD FOR QUANTIFICATION OF SOLUBLE LR11 - Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid. | 04-21-2011 |
20110033944 | METHOD FOR MEASURING HYPOCHLORITE ION - A method for measuring hypochlorite ion, which comprises the steps of: | 02-10-2011 |
20100330685 | DIAMINORHODAMINE DERIVATIVE - A compound represented by the following formula (I) or (II): | 12-30-2010 |
20100330600 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 12-30-2010 |
20100310597 | ANTI-OFLOXACIN MONOCLONAL ANTIBODY AND IMMUNOASSAY OF OFLOXACIN USING THE SAME - A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. | 12-09-2010 |
20100113786 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL - Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below. | 05-06-2010 |
20100047834 | METHOD FOR STABILIZING ALPHA-THROMBIN IN THROMBIN-CONTAINING SOLUTION - To provide a method for stabilizing unstable α-thrombin in a thrombin-containing solution, a solution containing stabilized α-thrombin, and a liquid fibrinogen assay reagent containing the solution. The method for stabilizing α-thrombin in a thrombin-containing solution, which includes adjusting the percentage of α-thrombin to 70% or more with respect to the amount of total thrombin in the thrombin-containing solution. | 02-25-2010 |
20100029010 | Diaminorhodamine Derivative - A compound represented by the following formula (I) or (II): | 02-04-2010 |
20090263915 | AGGLUTINATION INHIBITION ASSAY METHOD AND REAGENT - Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form. | 10-22-2009 |
20080249321 | Fluorescent Probes - A fluorescent probe which is represented by the following formula (wherein R | 10-09-2008 |